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Researchers have successfully applied exome sequencing to discover causal variants in selected individuals with familial, highly pene-
trant disorders. We demonstrate the utility of exome sequencing followed by imputation for discovering low-frequency variants asso-
ciated with complex quantitative traits. We performed exome sequencing in a reference panel of 761 African Americans and then
imputed newly discovered variants into a larger sample of more than 13,000 African Americans for association testing with the blood
cell traits hemoglobin, hematocrit, white blood count, and platelet count. First, we illustrate the feasibility of our approach by demon-
strating genome-wide-significant associations for variants that are not covered by conventional genotyping arrays; for example, one
such association is that between higher platelet count and an MPL c.117G>T (p.Lys39Asn) variant encoding a p.Lys39Asn amino
acid substitution of the thrombpoietin receptor gene (p ¼ 1.5 3 1011). Second, we identified an association between missense variants
of LCT and higher white blood count (p ¼ 4 3 1013). Third, we identified low-frequency coding variants that might account for allelic
heterogeneity at several known blood cell-associated loci:MPL c.754T>C (p.Tyr252His) was associated with higher platelet count; CD36
c.975T>G (p.Tyr325*) was associated with lower platelet count; and several missense variants at the a-globin gene locus were associated
with lower hemoglobin. By identifying low-frequency missense variants associated with blood cell traits not previously reported by
genome-wide association studies, we establish that exome sequencing followed by imputation is a powerful approach to dissecting
complex, genetically heterogeneous traits in large population-based studies.Introduction
Blood cell counts are heritable traits that represent
important intermediate phenotypes for a variety of cardio-
vascular, hematologic, oncologic, immunologic, and infec-
tious diseases. Traits such as hemoglobin and leukocyte or
white blood cell count (WBC) are known to differ by
ancestry. Through admixture mapping, the DARC null
allele has been identified as a major determinant of the
lower WBC in African-descended individuals as compared
with European Americans.1 Recent genome-wide associa-
tion studies (GWASs) have further contributed to our
understanding of the variability of blood cell traits
both within and across European-, African-, and Asian-
descended populations. For example, the CHARGE, CARe,
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concentration, hematocrit, red blood cell indices, WBC,
platelet count, and mean platelet volume (MPV).2–10
Lower-frequency or population-specific variants that are
not well captured by current genome-wide genotyping
platforms might account for inter-individual differences
in blood cell counts, particularly among individuals of
African ancestry. Alternatively, aggregations of rare vari-
ants might cause positive GWAS signals. Using the sickle
cell anemia HBB Glu6Val variant (MIM 141900) as an ex-
ample, Dickson et al. recently showed that multiple rare
variants can account for some of the signals reported in-
GWASs for common, complex traits.11 A number of other
rare genetic variants are known to contribute to familial
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variants or polymorphisms in these genes contribute to
blood cell traits in the general population is unknown.
Exome sequencing has recently allowed the discovery of
rare variants associated with highly penetrant Mendelian
disorders.12 The application of such next-generation
sequencing technologies to more complex phenotypes
in large population samples is currently limited by se-
quencing costs as well as technical and analytical chal-
lenges. The availability of genome-wide genotype data in
many large, population-based cohort studies, combined
with current genome-wide imputation approaches, offers
the opportunity to extend the assessment of rare coding
variants discovered through exome sequencing into larger
population-based samples. As proof-of-principle, we apply
this imputation approach to exome sequence data gener-
ated in a subset of African American cohort participants
from the National Heart, Lung, and Blood Institute
(NHLBI) Exome Sequencing Project (ESP). Using a reference
panel of 761 African Americans with exome sequence data,
we imputed newly identified variants into the full African
American cohorts comprising more than 13,000 individ-
uals with blood cell phenotypes and genome-wide SNP
genotyping data from four population-based studies. This
allowed us to assess whether lower-frequency variants
not well captured on current GWAS platforms are associ-
ated with blood cell traits in individuals of African ancestry
and to identify potential genomic loci that might con-
tribute to our understanding of hematopoiesis and blood
cell biology.
Subjects and Methods
Subjects
Participants included a total of 15,829 self-identified African
Americans with GWAS data from four population-based cohorts.
Of these individuals, 761 had undergone whole-exome se-
quencing as part of the first phase of the NHLBI ESP. Detailed
descriptions of each cohort are provided below. Clinical informa-
tion was collected by self report and in-person examination. All
participants provided written informed consent as approved by
local human-subjects committees. We excluded study participants
on the basis of pregnancy, cancer, or AIDS diagnosis at the time of
the blood count.
Women’s Health Initiative (WHI)
WHI is one of the largest (n ¼ 161,808) studies of women’s health
ever undertaken in the U.S. There are two major components of
WHI: (1) a clinical trial (CT) that enrolled and randomized
68,132 women ages 50–79 into at least one of three placebo-
control clinical trials (hormone therapy, dietary modification,
and supplementation with calcium and vitamin D); and (2) an
observational study (OS) that enrolled 93,676 women of the
same age range into a parallel prospective cohort study.13 A diverse
population including 26,045 (17%) women from minority groups
was recruited from 1993–1998 at 40 clinical centers across the U.S.
Of the CT and OS minority participants enrolled in WHI, 12,157
(including 8,515 self-identified African American and 3,642 self-
identified Hispanic subjects) who had consented to genetic
research were eligible for the WHI-SHARe GWAS project. Of theseThe Americaneligible individuals, 8,095 African Americans were included in the
current study.
Atherosclerosis Risk in Communities Study (ARIC)
The ARIC study is a prospective population-based study of athero-
sclerosis and cardiovascular diseases in 15,792 men and women,
including 11,478 non-Hispanic whites and 4,314 African Ameri-
cans drawn from four U.S. communities (suburban Minneapolis,
Minnesota; Washington County, Maryland; Forsyth County,
North Carolina; and Jackson, Mississippi).14 Only self-reported
African American participants are included in this analysis. Partic-
ipants were between ages 45 and 64 years at their baseline exami-
nation in 1987–1989, when blood was drawn for DNA extraction
and participants consented to genetic testing. Blood for complete
blood-count analysis was drawn at the baseline exam. After the
availability of adequate amounts of high-quality DNA was taken
into account and appropriate informed-consent and genotyping
quality-control and assurance procedures were put in place,
genome-wide genotype data were available for 2,989 African
Americans, of whom 2,779 were included in the current analysis.
Coronary Artery Risk Development in Young Adults
(CARDIA)
The CARDIA study is a prospective, multi-center investigation of
the natural history and etiology of cardiovascular disease in
a cohort of African Americans and whites who were 18–30 years
of age at the time of initial examination.15 The CARDIA sample
was recruited at random during 1985–1986 primarily from popu-
lations based in Birmingham, Alabama; Chicago, Illinois; and
Minneapolis, Minnesota; and Oakland, California from the
membership of the Kaiser-Permanente Health Plan. The initial
examination included 5,115 participants selectively recruited to
represent proportionate racial, gender, age, and education groups
from each of the four communities. From the time of initiation
of the study in 1985–1986 (baseline examination), six follow-up
examinations were conducted 2, 5, 7, 10, 15, 20, and 25 years later.
DNA extraction for genetic studies was performed at the 10 year
examination. After the availability of adequate amounts of high-
quality DNA was taken into account and appropriate informed-
consent and genotyping quality-control and assurance procedures
were put in place, genome-wide genotype data were available for
955 African Americans, of whom 953 were included in the current
analysis.
Jackson Heart Study (JHS)
The Jackson Heart Study (JHS) is a prospective population-based
study aimed at identifying the reasons for the high prevalence of
common complex diseases among African Americans in the Jack-
son, Mississippi metropolitan area. Such diseases include cardio-
vascular disease, type-2 diabetes, obesity, chronic kidney disease,
and stroke.16 During the baseline examination period (2000–
2004), 5,301 self-identified African Americans were recruited
from four sources, including (1) randomly sampled households
from a commercial listing; (2) ARIC participants; (3) a structured
volunteer sample that was designed to mirror the eligible popula-
tion; and (4) a nested family cohort. Unrelated participants were
between 35 and 84 years old, and members of the family cohort
wereR 21 years old when consent for genetic testingwas obtained
and blood was drawn for DNA extraction. On the basis of DNA
availability, appropriate informed consent, and genotyping results
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were available for 3,030 individuals, including 885 who are also
ARIC participants. In the current study, JHS participants who
were also enrolled in the ARIC study were analyzed with the
ARIC data set—for this reason, the JHS data set analyzed here is
defined as 2,145 individuals, of whom 2,132 are included in the
current analysis.
Blood Cell Phenotype Data
Samples for complete blood count (CBC) analysis were collected
at baseline by venipuncture into tubes containing ethylenediami-
netetraaetic acid (EDTA). CBCs were performed at local clinical
laboratories with automated hematology cell counters and stan-
dardized quality-assurance procedures.17 Hematocrit was reported
as a percentage, and hemoglobin was reported as g/dl. WBC and
platelet count were reported in millions of cells per ml. The abso-
lute numbers of eachWBC subtypewere calculated bymultiplying
the proportion of the WBC for each cell type by the total WBC
for each individual. For each blood cell trait, we excluded individ-
uals with (1) extreme outlying values (>10 standard deviations
from the mean) or (2) any highly discordant values among the
subset of ~3,000 participants who had serial CBC measurements
available in the cohort database at a subsequent time point. After
exclusions, data on blood-cell-count phenotypes were available
for up to 13,959 ESP African American participants. Data on
WBC subtype was available only in the ARIC, CARDIA, and JHS
participants.
Exome Sequencing, Variant Calling, and QC
Through ESP, exome sequence data were available on a total of 761
African American participants. These include 362 from WHI as
part of the WHI Sequencing Project (WHISP) and a total of 399
from ARIC (n ¼ 216) and JHS (n ¼ 166) as part of HeartGO. These
WHISP and HeartGO participants were selected on the basis of
primary phenotypes for ESP, which included extremes of body
mass index, blood pressure, LDL cholesterol, early-onset myocar-
dial infarction, and stroke. Exome sequencing was performed at
the University of Washington (SeattleGO) and the Broad Institute
(BroadGO). Initial quality control (QC) on all samples involved
sample quantification (PicoGreen), confirmation of high-molec-
ular-weight DNA, fingerprint genotyping, and sex determination.
Samples were failed if the total mass, concentration, or integrity of
DNA or the quality of preliminary genotyping data was too low or
if sex typing was discordant. After QC, ~3 mg genomic, nonampli-
fied DNA extracted from peripheral blood leukocytes was refor-
matted into 96-well plates for shotgun library preparation and
exome capture.18 Library construction steps included DNA frag-
mentation, end polishing and A-tailing, ligation of sequencing
adaptors, and PCR amplification. Sample shotgun libraries were
captured for exome enrichment with one of the following in-
solution capture products: CCDS 2008 (~26 Mb), Roche/Nimble-
gen SeqCap EZ Human Exome Library v1.0 (~32 Mb; Roche
Nimblegen EZ Cap v1), or EZ Cap v2 (~34 Mb). The fragment
size distribution of the libraries was highly consistent (typically
125 5 15 bp). Cluster amplification of denatured templates and
hybridization was performed via bridge PCR with Genome
Analyzer v3, Genome Analyzer v4, or HiSeq 2000 v2 cluster chem-
istry and flow cells (Illumina). Sequencing was performed on an Il-
lumina GAIIx or HiSeq 2000 with paired-end 76 base runs or 50
base runs, respectively.
For read mapping and variant analysis, samples were aligned to
a human reference (hg19) with BWA (Burrows-Wheeler Aligner).19
Data were processed with the Genome Analysis ToolKit (GATK796 The American Journal of Human Genetics 91, 794–808, Novembrefv1.290520). Reads were locally realigned (GATK IndelRealigner),
and their base qualities were recalibrated (GATK Table Recalibra-
tion). Variant detection and genotyping were performed on both
exomes and the flanking 50 bp of intronic sequence. Typical
mean coverage of the target was 603–803. In brief, we took
a two-step approach for discovering and genotyping candidate
sites. First, we generted genotype likelihood files (GLFs) by using
samtools pileup on individual binary alignment map (BAM) files.
Next, we used glfMultiples—a multi-sample variant caller—to
generate initial single-nucleotide variant (SNV) calls.21 This
process allowed us to perform multi-sample calling of variants
across thousands of samples. In brief, the distribution of observed
bases and quality scores at each location (conditional on the true
genotype) was modeled according to the MAQ model.22 Using
maximum likelihood, we then estimated an allele frequency for
each site under the assumption that genotypes were segregating
in Hardy-Weinberg proportions. For the initial variant calls, we
assumed that the prior probability that a site was polymorphic
was 0.0091, corresponding to an estimate of the prior for a segre-
gating site in a simple population-genetics model and an esti-
mated per-sample, per-base-pair heterozygosity of q ¼ 0.001. We
assumed that transition and transversion mutations were equally
likely, thereby allowing the use of transition-transversion (Ti/Tv)
ratio as a diagnostic of SNP call quality. Genotypes for each site
and corresponding posterior probabilities were then calculated
with the Bayes theorem, for which the Hardy-Weinberg propor-
tions were used as priors and the MAQ error model was used for
describing the conditional probability of bases and quality scores
given the true genotype.
After these initial SNV calls were generated, we re-examined the
BAMfiles to collect additional information about each variant site.
Filters considered the total read depth, the number of individuals
with coverage at the site, the fraction of variant reads in each
heterozygote, the ratio of forward and reverse strand reads
carrying reference and variant alleles, and the average position
of variant alleles along a read. All individual exome-sequencing
data were evaluated against the QC metrics of both bulk and
per-sample properties, including the distribution of novel and
known variants relative to dbSNP, fingerprint concordance, Ti/Tv
ratio, Het/Hom ratio, library complexity, capture efficiency and
uniformity, and coverage distribution (90% atR 83 was required
for completion at the University of Washington; 70% at > 203
was required for completion at the Broad Institute).
Variant data for each sample were formatted (variant call format
[VCF]) as ‘‘raw’’ calls for all samples. The final SNP call set included
variants that were called with posterior probability>99% (glfMul-
tiples SNP quality >20), that were >5bp away from an indel de-
tected in the 1000 Genomes Pilot Project, that were covered by
at least one read in 85% of samples, and that had total depth across
samples of between 2,500 and 2,500,000 reads (~1–100 reads per
sample). Sites for which >65% of reads were heterozygotes
carrying the variant allele or where the absolute squared correla-
tion between allele (variant or reference) and strand (forward or
reverse) was >0.15 were excluded.
Genotype-wide Genotyping and QC
The Affymetrix 6.0 platform was used for genome-wide geno-
typing in all participants, either at Affymetrix for the WHI-
SHARe project or at the Broad Institute for the NHLBI Candidate
Gene Association Resource (CARe) consortium (ARIC, CARDIA,
and JHS). Genotyping and quality-control procedures for
both WHI-SHARe and CARe have been described in detail.6,10,23er 2, 2012
Principal-component analysis was implemented in EIGEN-
STRAT24 within each African American cohort on cleaned
genome-wide-association (GWA) genotype data. DNA samples
with a genome-wide genotyping success rate of <90%, duplicate
discordance or sex mismatch, genetic ancestry outliers (as deter-
mined by cluster analysis performed via principal-component
analysis), SNPs with a genotyping success rate of <95%, mono-
morphic SNPs, SNPs with minor-allele frequency (MAF) <1%,
and SNPs that mapped to several genomic locations were removed
from the analyses. A total of 838,337 Affy6.0 SNPs were used for
genotype imputation, as described below.
Imputation of ‘‘Virtual Exomes’’ and QC
We used the 761 African American ESP participants as a reference
sample to impute variants identified by exome sequencing into
the larger target sample of 15,829 African Americans with GWAS
data from WHI, ARIC, CARDIA, and JHS. Specifically, we con-
structed, by using MaCH 1.0.18,25 an internal reference of 1,522
phased haplotypes from the 761 African Americans with both
whole-exome sequencing and Affymetrix 6.0 genotyping data.
We also prephased the remaining ARIC, CARDIA, JHS, and WHI
participants with genotyping data only. We then used mini-
mac26 to impute genotypes at markers discovered in ESP for the
15,829 African Americans. Minimac is a low-memory, computa-
tionally efficient implementation of the MaCH algorithm25 for
genotype imputation and is designed to work on phased geno-
types. It can handle very large reference panels with hundreds or
thousands of haplotypes. After careful QC and marker and strand
matching, we imputed 420,876 markers from 838,337 markers on
Affymetrix 6.0. Given the size of the reference panel, variants with
MAF <0.1% were further excluded from association analyses,
leaving 368,093 exome-sequencing-identified variants of MAF
0.1% or greater. Prior to data analysis, SNPs were additionally
excluded if imputation quality metrics (Rsq, which is equivalent
to the squared correlation between proximal imputed and geno-
typed SNPs) were less than the MAF-based thresholds chosen
such that within each MAF category, SNPs passing the QC
threshold had an average Rsq of 0.8 or more. After exclusion based
on MAF and imputation quality scores, 178,954 imputed exome
variants remained in the data set for association analysis. For post-
imputationQC, we evaluated imputation quality by twomethods:
(1) comparing experimental genotypes from the Metabochip in
a subset of 1,830 among the 8,059 WHI individuals;27 and (2)
imputing the 761 reference individuals one at a time: this involves
masking genotypes at the exome SNPs for one reference individual
at a time, imputing the masked genotypes by using the remaining
1,520 haplotypes, and comparing the imputed with the masked
experimental genotypes. The two evaluation methods resulted
similar conclusions, confirming that using an average Rsq of R
0.8 is an effective postimputation filter for rare variants.
Statistical Analysis
Association analyses for quantitative blood cell traits were per-
formed separately for the WHI and CARe cohorts (ARIC, CARDIA,
and JHS) via linear regression as implemented in MACH2QTL v.
1.08. Allelic dosage at each SNP (a value between 0.0 and 2.0,
calculated on the basis of the probability of each of the three
possible genotypes) was used as the independent variable,
adjusted for primary covariates of age, sex, cohort, and global
ancestry, as represented by principal-component analysis of the
GWA data. All WBC traits were natural-log-transformed so that
the distributions of the phenotypic data would be normalized.The AmericanThe WBC analysis was additionally adjusted for genotype at
rs2814778, the African-specific DARC or Duffy blood group null
variant rs2814778, which is known to account for 15%–20% of
the WBC variance among African Americans.1,6
For each blood cell phenotype, WHI and ARIC, CARDIA, and
JHS study-level regression results were combined via inverse-vari-
ance weighted fixed-effects meta-analysis to derive an overall
p value and effect estimate for each SNP. Meta-analyses were im-
plemented with the METAL28 software and corrected for genomic
inflation factors (l). Between-study heterogeneity of results was
assessedwith Cochran’sQ statistic and the I2 inconsistencymetric.
Because genome-wide association testing was performed for more
than 1 million genotyped and imputed SNPs, we used a signifi-
cance threshold of a ¼ 2.5 3 108, which has been suggested for
African-ancestry populations so that an overall type 1 error rate
of 5% can be maintained. We did not additionally correct for
testing four phenotypes.
To detect transitions in ancestry along the genome, we used
a Hidden Markov Model and local haplotype structure to estimate
locus-specific ancestry (probabilities of whether an individual has
0, 1, or 2 alleles of African ancestry) at the LCT gene locus for each
participant.29,30 Phased haplotype data from the HapMap CEU
(Utah residents with ancestry from northern and western Europe
from the CEPH collection) and YRI (Yoruba in Ibadan, Nigeria)
individuals were used as reference panels. To assess the impact of
local ancestry at the LCT locus on WBC phenotype association,
we repeated SNP genotype-WBC linear regression analysis and
adjusted for local ancestry proportion as a covariate. For annota-
tion of coding variants, we used CONsensus DELeteriousness
(Condel) scores to predict the impact of nonsynonymous single-
nucleotide variants on protein function.31Gene Expression Quantitative-Trait Loci (eQTL)
Analysis
The associated LCTmissense variants and their correlated proxies
(r2 > 0.80) were identified in the YRI in the 1000 Genomes Project
data. We queried these SNPs against several web data sources to
determine potential eQTLs linked to the WBC signal: SCAN
(SNP and CNV Annotation Database) including YRI gene eQTLs
in lymphoblastoid cell lines (LCLs)32 and RNA-sequencing eQTLs
in YRI LCLs from.33 Additional cis-eQTL results were queried from
an assembled database of associations in a wide variety of tissues
derived primarily from European-ancestry populations: fresh
lymphocytes,34 fresh leukocytes,35 leukocyte samples in individ-
uals with Celiac disease,36 LCLs derived from asthmatic chil-
dren,37 HapMap LCLs from three populations,38 HapMap CEU
LCLs from a separate study,39 peripheral blood monocytes,40,41
omental42 and subcutaneous adipose cells,42,43 stomach42 and
whole blood samples,43,44 endometrial carcinomas,45 brain cortex
from two studies,41,46 prefrontal cortex,47 brain regions including
prefrontal cortex, visual cortex, and cerebellum from three large
studies, liver,42,48–50 osteoblasts,51 skin,52 and additional fibro-
blast, T cell, and LCL samples.53Assessment of Fine-Scale Population Structure at LCT
Recently, Mathieson and McVean54 raised a concern that existing
approaches (such as principal-component adjustment) might not
adequately control for population stratification in rare-variant
association studies. In such a situation, any rare variants that
have higher frequencies within a sharply defined geographic
region will appear to be associated with the phenotype. ToJournal of Human Genetics 91, 794–808, November 2, 2012 797
Table 1. Characteristics of ESP African American Participantsa
Study
Atherosclerosis Risk
in Communities (ARIC)
Coronary Artery Risk
Development in Young
Adults (CARDIA)
Jackson Heart
Study (JHS)
Women’s Health
Initiative (WHI)
Sample size 2779 953 2132 8095
Age, years (SD) 53.3 (5.8) 24.4 (3.8) 50.0 (12.1) 61.6 (7.0)
% Female 63.2 61.3 60.8 100
Hemoglobin, g/dL (SD) 13.2 (1.5) 13.7 (1.5) 13.1 (1.5) 12.9 (1.0)
Hematocrit, % (SD) 40.2 (4.5) 41.1 (4.5) 39.5 (4.3) 39.1 (3.0)
WBC (SD) 3 109/liter 5.69 (1.85) 5.93 (2.01) 5.66 (1.81) 5.63 (1.86)
Platelets (SD) 3 109/liter 257.0 (66.2) 282.3 (68.5) 256.6 (65.7) 250.5 (62.6)
Neutrophils D) 3 109/liter 2.89 (1.45) 3.11 (1.57) 3.15 (1.51) NA
Lymphocytes (SD) 3 109/liter 2.17 (0.75) 2.23 (0.84) 1.96 (0.66) NA
Monocytes (SD) 3 109/liter 0.344 (0.197) 0.314 (0.184) 0.390 (0.145) NA
Eosinophils (SD) 3 109/liter 0.165 (0.165) NA 0.139 (0.126) NA
Basophils (SD) 3 109/liter 0.037 (0.043) 0.046 (0.044) 0.033 (0.022) NA
Abbreviations are as follows: SD ¼ standard deviation; NA ¼ not available.
an ¼ 13,959.formally test this possibility, we performed genome-wide associa-
tion testing in which we treated carrier status at LCT rs35940156
as the ‘‘disease phenotype’’ or dependent variable in a regression
model; variants that were enriched among carriers of
rs35940156 were expected to show small p values. Specifically,
we defined a quantitative phenotype by the number of minor
alleles at LCT s35940156. We then performed genome-wide asso-
ciation analysis by adjusting for principal components and used
METAL to combine the results from the CARe and WHI-SHARe
cohorts. As references, we selected 58 control SNPs, which we
selected to have the same minor-allele frequencies as rs35940156
in the 1000 Genomes CEU and YRI populations (~2.2% in YRI,
2% in the ESP-sequenced individuals, and 0% in CEU) and
repeated the genome-wide scan for the phenotype or population
stratum defined at each of these control SNPs. To eliminate linkage
disequilibrium (LD) at linked regions, we removed variants
residing on the same chromosomes as the respective control SNPs.Results
We performed an exome-wide analysis of four hematologic
traits (hemoglobin, hematocrit, WBC, and platelet count)
in African Americans from four population-based cohorts
(ARIC, CARDIA, JHS, and WHI). The characteristics of
each cohort are summarized in Table 1. We imputed
SNPs that we had identified by sequencing 761 African
Americans from the NHLBI GO ESP to the full popu-
lation-based sample of 13,959 African Americans. We
used Affymetrix 6.0 genotype and blood-cell-count data
for hemoglobin, hematocrit, WBC, and platelet-count
phenotypes.
In contrast to conventional genome-wide SNP analyses,
the variants interrogated in the current study were en-
riched in coding regions and had lower MAFs, and they798 The American Journal of Human Genetics 91, 794–808, Novembincluded 178,954 high-quality, exome-sequencing-identi-
fied variants with a MAF of 0.1% or more. Of these
178,954 variants, 104,386 are present in dbSNP (build
131) and 1000 Genomes, 13,219 are in dbSNP only, and
19,979 are in 1000 Genomes only. Thus, 41,370, or 23%,
of the imputed variants are ‘‘novel.’’ The distribution of
the 178,954 high-quality imputed exome variants by func-
tional category is shown in Table S1 in the Supplemental
Data available with this article online. The average depth
of coverage for the 100,902 high-quality variants located
within exons was 101.05. The average coverage depth for
the 78,052 high-quality variants located outside exons
was 61.89. Of the nonexonic variants, 94.4% were located
within 50 bp of an exon, and the median distance from an
exon was 22 bp.
Because lower-frequency variants are more challenging
for imputation, we have applied more stringent postimpu-
tation quality filtering by using higher Rsq thresholds for
rarer variants. Specifically, we chose an Rsq threshold of
0.9, 0.8, 0.6, 0.3, and 0.3 for SNPs with MAF 0.1%–0.5%,
0.5%–1%, 1%–3%, 3%–5%, and >5%, respectively. Under
these criteria, 92.9% of SNPs with MAF > 5% passed QC,
whereas only 7.3% of SNPs with MAF ¼ 0.1%–0.5% passed
QC (Table 2). By comparing imputed genotypes with
experimental genotypes from the Metabochip,27 we esti-
mated that the information content retained (measured
by dosage r2, squared Pearson correlation between imputed
and experimental genotypes) is > 81% across the MAF
categories (Table 2). To further evaluate the sensitivity of
our imputation, we examined the coverage of coding
SNPs found on the Illumina Exome-Chip; 30.6% of the
coding variants on the Exome-Chip were covered by
the raw imputed data, whereas 15.4% were covered byer 2, 2012
Table 2. Filtering of Exome Variants on the Basis of Allele Frequency and Imputation Quality
MAF
Rsq
Threshold
Number of
Imputed ESP SNPs
Number of QCþ
Imputed ESP SNPs
Percent QCþ
Imputed ESP SNPs Average Dosage r2
0.1%–0.5% 0.9 135,942 9,885 7.3% 83.17%
0.5%–1% 0.8 52,155 17,872 34.3% 84.01%
1%–3% 0.6 69,158 47,801 69.1% 81.88%
3%–5% 0.3 26,060 23,882 91.6% 81.04%
>5% 0.3 84,478 78,507 92.9% 84.40%the imputed data that passed QC. These results met our
expectations given that the imputation reference panel
(761 African Americans) was less than 1/3 the size of the
African American sample that was used in the design of
the Exome-Chip array.
The genomic-control-corrected QQ plot for hemoglobin,
WBC, and platelet count are shown in Figure S1, and the
corresponding Manhattan plots are shown in Figure S2.
Several regions reached genome-wide significance at the
threshold of p < 2.5 3 108 (Table 3), as described in
further detail below. GWAS findings for common variants
derived from conventional genotyping arrays such as Affy-
metrix 6.0 and HapMap imputation have been reported in
African Americans for WBC,6 platelet count,10 and hemo-
globin and hematocrit.8 Therefore, only loci newly identi-
fied through exome imputation are highlighted here.
Hemoglobin and Hematocrit
Globin Gene Variants are Significantly Associated with Hemo-
globin and Hematocrit
The known rs334 sickle cell b-globin p.Glu6Val variant of
HBB (MIM 141900) (MAF ¼ 0.05), which is not covered
by conventional GWA panels, was significantly associated
with lower hematocrit (p ¼ 5.7 3 1011) and hemoglobin
(p¼ 9.73 106). Ten SNPs located on the terminal portion
of the long arm of chromosome 16 near the a-globin
locus were significantly associated with hemoglobin
(Table 3; see also Table S3). The SNP most strongly associ-
atedwithhemoglobinwas rs9924561 (MAF¼0.07), located
in the next-to-last intron of ITFG3 (p ¼ 6.6 3 1024)
(Figure 1A). Another common variant (LUC7L [MIM
607782] rs1211375) on chromosome 16p13was previously
associated with hemoglobin in African Americans.8 Of
the remaining chromosome 16 a-globin-region SNPs sig-
nificantly associated with hemoglobin, two are located
within coding sequence (both synonymous): rs13335497
(c.423G>A [p.Ser141 ¼]; RefSeq NM_032039.2) of ITFG3
(MAF ¼ 0.07, p ¼ 1.8 3 1021) and rs11863726 (c.93A>G
[p.Glu31 ¼ ]; RefSeq NM_005331.4) of HBQ1 (MAF ¼
0.27, p ¼ 8.9x 1011). ITFG3 rs13335497 is in strong LD
with ITFG3 rs9924561 (r2 ¼ 0.98). In contrast, HBQ1
(MIM 142240) rs11863726 is weakly correlated with other
hemoglobin-associated SNPs in the region (maximum r2
¼ 0.35 with rs9929571) and is 3 bp from a splice junction
in the gene encoding fetal hemoglobin theta. SeveralThe Americanlower-frequency (MAF ¼ 0.02–0.03) nonsynonymous
SNPs in the a-globin cluster were nominally associated
with lower hemoglobin (Table S2): rs76613236 (c.155G>C
[p.Gly52Ala]; RefSeq NM_005331.4) located in HBQ1
(hemoglobin-theta), rs143256173 (c.45C>A [p.Asp15Glu];
RefSeq NM_001003938.3) in HBM (hemoglobin-mu [MIM
609639]), and rs144091859 (c.1600G>A [p.Asp534Asn];
RefSeq NM_032039.2) in ITFG3 (p values in the range of
105–107). These three low-frequency coding variants of
the fetal hemoglobin genes are in strong LD with one
another (pair-wise r2z 0.9) but are largely independent of
the other hemoglobin-associated variants in this region
(maximum r2 z 0.2 with rs1211375). Conditional regres-
sion analyses performed in a step-wise manner with WHI
data (n ¼ 8,087) suggest that this region might contain
several independent hemoglobin association signals,
tagged by the common rs13335497 and rs11863726
variants, in addition to the lower frequency ITFG3
c.1600G>A (p.Asp534Asn) variant (Table S3). In a smaller
subset of 1,800 WHI African American participants
who underwent direct genotyping of rs144091859,
we confirmed that the minor allele of ITFG3 c.1600G>A
(p.Asp534Asn) was associated with 0.248 5 0.130 g/dl
lower hemoglobin (p ¼ 0.05).
Additional Loci for Hemoglobin and Hematocrit
Additional SNPs associated with red blood cell phenotypes
in African Americans at nominally significant p values
(range of 105–107) confirmed previous GWAS results in
other ethnicities (Tables S2 and S4). Within ABO (MIM
110300) on chromosome 9, several common coding
SNPs that tag the B blood group antigen (such SNPs
include rs8176746, which confers a p.Met266Leu substitu-
tion in exon 7) were associated with higher hemoglobin in
African Americans. The association between SNPs tagging
the B blood group antigen and higher hemoglobin was
recently reported in a Japanese GWAS.4 A common
rs3772219 missense variant (c.1021T>G [p.Leu341Val];
RefSeq NM_001128616.1) of ARHGEF3 (MIM 612115),
which encodes rho guanine-nucleotide exchange factor 3
(RhoGEF3), was associated with higher hematocrit. A
distinct set of intronic ARHGEF3 polymorphisms (tagged
by rs12485738) has been associated with platelet count
and mean platelet volume in European Americans,9,55
and the ARHGEF3 gene product was recently shown to
be involved in iron uptake by erythroid cells.56Journal of Human Genetics 91, 794–808, November 2, 2012 799
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Associations of Nonsynonymous Variants of LCT with higher
WBC
Several SNPs on chromosome 2q21 were significantly asso-
ciatedwithahigherWBC(Table3; see alsoTable S5).Mostof
these SNPs liewithin a ~350 kb region containingR3HDM1,
MCM6 (MIM 601806), LCT (MIM 603202), and DARS
(MIM 603084) (Figure 1B). The most strongly associated
(p ¼ 3 3 1013–4 3 1013) were two lower-frequency LCT
nonsynonymous coding variants, rs35837297 (c.301A>G
[p.Ser101Gly]; RefSeq NM_002299.2) and rs35940156
(c.1318G>A [p.Val440Ile]; RefSeq NM_002299.2). These
two LCT missense variants are in almost perfect LD with
one another (r2 > 0.99) and were also in strong LD (r2 >
0.75)with another nonsynonymous SNP significantly asso-
ciated with WBC, RAB3GAP1 (MIM 602536) rs76927619
(c.669G>T, RefSeq NM_012233.2), which is located more
than700kbdownstreamofLCTandencodesap.Leu223Phe
substitution in the catalytic subunit of Rab3 GTPase-acti-
vating protein. Upon adjustment for either of the LCT
missense variants, the association between RAB3GAP1
rs76927619 andWBC was markedly attenuated (p ¼ 0.1).
Ancestry-Adjusted Analyses of LCT-Containing Chromosomal
Region 2q21
Because ethnic background is a major determinant of
WBC, careful assessment of population stratification is
warranted by the presence of complex patterns of genetic
variation on chromosomal region 2q21, which has
undergone strong recent selective pressure in Europeans
and Africans.57 As expected, global African ancestry was
strongly associated with lower WBC. In contrast, local
African ancestry in the LCT region showed a weaker,
but statistically significant, association with higher WBC
(p ¼ 0.001). We repeated the LCT missense SNP-WBC
association analyses in the 8,095 WHI participants and
adjusted for global ancestry, the first ten principal com-
ponents derived from GWAS data, or local ancestry, as
well as for four U.S. geographic regions (Table S6). The
associations between WBC and the rare missense LCT
variants were robust to all of these covariate adjustments,
as well as to adjustment for ethnicity-specific LCT
promoter SNPs (rs4988235, rs3806502, rs3087343, and
rs749017) that have been associated with the lactase-
persistence phenotype (MIM 223100).57 When stratified
by the estimated local number of European versus African
chromosomes, the LCT rs35837297-WBC association
in WHI was present among 4,841 African Americans
who carry two African chromosomes (b ¼ 0.083 5 0.018;
p ¼ 3.7 3 106), but not among the 3,462 African
American who carry at least one European LCT chromo-
some (b ¼ 0.012 5 0.040; p ¼ 0.76).
Assessment of Fine-Scale Population Structure due to LCT
Missense Variants
Recently, Mathieson and McVean54 raised a concern that
existing approaches (such as PC adjustment) might not
adequately control for population stratification in rare-
variant association studies. This argument assumes thater 2, 2012
Figure 1. Regional Plots of Genetic Loci Associated with Blood Cell Traits
Shown are regional association plots generated with LocusZoom for (A) the chromosome 16 a-globin locus and hemoglobin; (B) the
chromosome 2 LCT region and WBC; (C) MPL on chromosome 1 and platelet count; and (D) the CD36 locus on chromosome
7 and platelet count. The color of each single-nucleotide variant (SNV) indicates the level of pairwise linkage disequilibrium (LD) based
on r-squared relative to the lead SNV in the region. r-squared values were calculated from 1000 Genomes YRI. SNVs with missing LD
information are shown in gray. Included in these plots are either SNVs that were imputed from exome sequence data or any regional
SNVs that were genotyped with the Affymetrix 6.0 array.the phenotype distribution is substantially shifted within
a ‘‘small, sharply defined [geographic] region’’54. In such
a situation, any rare variants that have higher frequencies
in this geographic region will appear to be associated with
the phenotype. If this were the case, we would expect addi-
tional (noncausal) rare variants to show similar geographic
clustering; in other words, we would expect an excess of
unlinked rare variants showing strong LD with the LCT
missense variants. When we compared the LCT missense
variant rs35940156 to 58 control SNPs selected on the
basis of their having the same minor-allele frequencies as
rs35940156 in the 1000 Genome’s CEU and YRI popula-
tions, we found no evidence that it was associated with
an excess of unlinked markers across the genome. The
p value distribution when rs35940156 was used as
the stratum definition is not significantly different from
the distribution when the control SNPs defined the
stratum (Figure S3). The lower extremes of the p value
distributions for association with unlinked markers are
also indistinguishable between the LCT and the controlThe AmericanSNPs; for example, the 0.01% quantile ranges from 4.3 3
106–5.1 3 105 and is 2.0 3 105 for the LCT-defined
phenotype. These results argue against the notion that
the observed LCT-WBC associations represent an artifact
of a geographically isolated population stratum in which
WBC is substantially different but is due to variants
unlinked to LCT.
Validation and Functional Genomic Analysis of the Association
between the LCT Missense Variant and WBC
The imputation quality for the LCT missense variants was
excellent (Rsq > 0.98). Nonetheless, we performed valida-
tion of this finding by genotyping rs35940156 in a subset
of 5,229 African American participants (624 from WHI,
2,795 from ARIC, 824 from CARDIA, and 1,756 from
JHS). The minor allele was associated with a 0.168 5
0.034 increase in the natural log unit in WBC (p ¼ 6.3 3
107), confirming the association. We also performed gen-
otyping in 1,029 independent African American samples
(305 from WHI and 724 from the Cardiovascular
Health Study), further validating this WBC associationJournal of Human Genetics 91, 794–808, November 2, 2012 801
(b ¼ 0.102 5 0.043; p ¼ 0.019). The overall p value
combining discovery and validation samples was 2.3 3
1014. Analysis of the LCT missense SNPs in the three
cohorts (ARIC, CARDIA, JHS) with data available on
WBC subtypes (n ¼ 5,105) showed the associations with
neutrophil andmonocyte counts were strongest (Table S7).
Using HapMap and 1000 Genomes YRI data for further
examination of the LCT region revealed extensive LD
between the WBC-associated missense variants and
numerous other SNPs in the chromosomal region 2q21.
Interestingly, the extended region of LD spans ~1 Mb in
Africans and includes CXCR4 (MIM 162643), which
encodes a leukocyte chemokine receptor involved in
hematopoietic stem cell migration and leukocyte recruit-
ment.58 To further assess the functional significance of
the LCT variants associated with WBC (particularly
whether these SNPs have any regulatory effect on expres-
sion of CXCR4), we queried these SNPs and correlated
proxies (r2 > 0.8) against a database of >30 gene eQTL
data sets, as well as RNA-sequencing eQTLs and SCAN.
No significant cis-eQTLs were identified with the LCT
missense variants or their correlated proxies. In summary,
we have identified an association between a low-frequency
African-ancestry-specific missense variant of LCT and
higher WBC, but the biologic mechanism underlying
this genetic association requires further study.
Platelet Count
Association of African-Specific MPL Lys39Asn Missense Variant
with Higher Platelet Count
The strongest association signal for platelet count
was rs17292650 (MAF ¼ 0.04, p ¼ 1.5 3 1011). This
African-ancestry-specific missense variant (c.117G>T
[p.Lys39Asn]; RefSeq NM_005373.2) is located in exon 2
ofMPL (MIM 159530), which encodes the thrombopoietin
receptor on platelets and megakaryocytes (Table 3,
Figure 1C). The c.117G>T [p.Lys39Asn] MPL variant has
not been identified in prior GWASs, although it was previ-
ously discovered through a candidate-gene sequencing
study of African Americans with essential thrombocyto-
sis.59 In a subset of 1,872 WHI African American partici-
pants who underwent genotyping of rs17292650, we
confirmed that the minor allele of c.117G>T was associ-
ated with a 25.5 5 5.31 higher platelet count (p ¼ 1.7 3
106). A rare (MAF ¼ 0.005) nonsynonymous variant
rs141311765 in exon 5 of MPL (c.754T>C [p.Tyr252His];
RefSeq NM_005373.2) was independently associated with
higher platelet count (p ¼ 4 3 105).
Additional Suggestive Loci for Platelet Count
Variants within CD109 (MIM 608859), CD36 (MIM
173510), and ITGB3 (MIM 173470), which encode several
platelet surface glycoproteins involved in platelet adhesion
and aggregation as well as platelet alloantigen formation,
had p values for association with platelet count in the
range of 105–107. (Table S8) GWAS recently showed
that rs17154155, a common intronic variant of CD36,
is associated with higher platelet count in African802 The American Journal of Human Genetics 91, 794–808, NovembAmericans.10 In the current exome-imputed data set, two
lower-frequency coding variants of CD36 were associated
with lower platelet count: these variants were rs3211938
(c.975T>G [p.Tyr325*]; RefSeq NM_000072.3) and
rs3211862 (c.158_159insG [p.Asn53Lysfs*4]; RefSeq NM
000072.3) (Figure 1D). In conditional regression analyses,
the platelet-count associations for these three CD36 vari-
ants (intronic, nonsense, and frameshift) all appeared to
be conditionally independent of one another (Table S9).Discussion
We performed exome sequencing in a reference panel of
761 African Americans and imputed these samples into
a much larger target sample of more than 13,000 from
the original African American cohorts. We confirmed the
association of a lower-frequency MPL receptor missense
variant, c.117G>T (p.Lys39Asn), with higher platelet
count in African Americans. We also identified a genome-
wide association between two low-frequency LCT nonsy-
nonymous coding variants (c.301A>G [p.Ser101Gly] and
c.1318G>A [p.Val440Ile]) and higher WBC in African
Americans. Lastly, we identified associations of low-
frequency coding variants at existing blood-cell-associated
genetic loci: MPL c.754T>C (p.Tyr252His) was associated
with higher platelet count; CD36 c.975T>G (p.Tyr325*)
was associated with lower platelet count; and several
missense variants at the a-globin locus were associated
with lower hemoglobin. Together, these results demon-
strate the utility of an ‘‘exome imputation’’ approach for
identifying low-frequency coding variants associated
with complex blood cell phenotypes in large population-
based samples. The implications of these findings for
particular blood cell phenotypes and related disorders are
discussed below.Red Blood Cell Disorders
Usinga cardiovascular gene-based-tagSNPgenotypingarray
in the population-based CARe consortium (which includes
the cohorts JHS, ARIC, and CARDIA), Lo et al. reported
a common variant that was located within the a-globin
locus on chromosomal region 16p13 (LUC7L rs1211375)
and was associated with lower hemoglobin, mean corpus-
cular hemoglobin, andmean corpuscular volume inAfrican
Americans.8 This SNP might tag an African a-globin
copy-number polymorphism (CNVR6569) that is absent
in Europeans,8 consistent with the knownworldwide distri-
bution of a-thalassemia copy-number variants.60 We find
evidence for additional genetic complexity and allelic
heterogeneity at the a-globin locus at chromosomeal
region 16p13 in African Americans; such evidence in-
cludes the association of hemoglobin with rs13335497
(c.423G>A, p.Ser141 ¼), a common synonymous variant
of ITFG3, which encodes integrin-a FG-GAP repeat-contain-
ing-3. The function of the ITFG3 gene product is unknown,
although it is expressed in an erythroleukemia cell line61er 2, 2012
and other common polymorphisms of this gene have
been associated with red blood cell indices in European
and Japanese GWASs.2,4 Several of the lower-frequency
nonsynonymous hemoglobin-associated variants (HBQ1
c.155G>C [p.Gly52Ala], HBM c.45C>A [p.Asp15Glu], and
ITFG3 c.1600G>A [p.Asp534Asn]) are predicted to have
deleterious effects on protein function. Nonetheless, the
functions of the embryonic theta-globin and mu-globin
genes are poorly understood; these genes are expressed
at low levels in adult erythroid cells but are not translated
into detectable globin protein.62,63 Sequence analysis
of the 1000 Genomes data has revealed that several
common and rare structural variants at the a-globin locus
segregate in African populations (R. Handsaker and
S. McCarroll, personal communication), consistent with
the clinical observation thatmanydifferentDNA rearrange-
ments can cause a-thalassemia. Thus, it is possible that the
independent single-nucleotide variants associated with
lower hemoglobin at the a-globin locus in our data set in
fact capture thesedifferent structural variants.Alternatively,
one or more of these single nucleotide variants could
directly disrupt normal a-globin gene expression, as has
been previously reported.64 Establishing whether any of
these African American hemoglobin-associated single-
nucleotide variants are themselves "causal" or are proxies
for additional a-thalassemia-related copy-number variants
will require additional functional and population-genetics
study.
WBC
The WBC-associated LCT missense variants rs35837297
(c.301A>G; p.Ser101Gly) and rs35940156 (c.1318G>A;
p.Val440Ile) are distinct from the cluster of functional
promoter variants that cause lactase persistence. The
lactase-persistence SNPs are located ~14 kb upstream of
LCT and have arisen on different population-specific
haplotype backgrounds (13910T in Europeans and
13907G, 13915G, and 14010C in East Africans)
through convergent evolution as a result of positive selec-
tion.57,65 The WBC association we observed for the low-
frequency LCT coding variants was robust to adjustment
of the European lactase-persistence variant 13910T,
whereas the major East African lactase-persistence variant
14010C is absent in Nigerian Yoruba and African Ameri-
cans. Hence, the observed WBC association at the LCT
missense variants is unlikely to be due to population struc-
ture related to natural selection of the lactase-persistence
phenotype. The WBC association observed for the low-
frequency LCT coding variants was also robust to adjust-
ment for genome-wide, locus-specific ancestry, as well as
leading principal components. The LCT-WBC association
was present only among African Americans who carried
two African chromosomes in the LCT genomic region,
further reducing the likelihood of confounding due to
continental ancestry or gross-scale geographic structure.
Finally, we found no evidence suggesting that the associa-
tion was due to confounding of a small and undetectedThe Americanpopulation stratum, as stipulated by a model in Mathieson
and McVean.54
The mechanisms behind the association of LCT variants
with higher WBC are not known. We reviewed the Mouse
Phenome Database66 and found Lct expression in the
mouse is associated with CD8 count, suggesting a link to
intestinal immunity and an effect of dietary exposure to
lactose. It is possible that the WBC-associated LCT coding
variants are proxies for a regulatory variant that controls
expression or function of the nearby gene, CXCR4. Alter-
natively, it is possible that there exist functional CXCR4
coding variant(s) that are in LD with the LCT missense
variants and that these causal CXCR4 variant(s) were not
captured (or failed QC) during the original exome-
sequencing study. Rare activating mutations in CXCR4
are associated with WHIM syndrome (MIM 193670),
a congenital immunodeficiency disorder characterized by
infections and severe leukopenia.67 From an evolutionary
standpoint, the complex haplotype pattern and extensive
LD in the LCT-CXCR4 region among African populations
suggests the possibility that additional selective sweeps
might have occurred within Africa for reasons unrelated
to milk consumption, perhaps due to host interactions
between blood cells and pathogens.57 Common variants
of two other chemokine-related genes, DARC (MIM
613665) and CXCL2 (MIM 139110), are associated with
WBC.5,6 Both the DARC null variant and low WBC are
highly prevalent in Africa, where theDARC variant confers
resistance to malarial infection (MIM 611162).
Platelet Count
Through a candidate-gene sequencing study, the African-
specific MPL c.117G>T (p.Lys39Asn) variant was associ-
ated with reduced platelet protein MPL expression and
mild thromobocytosis in heterozygotes and with more
severe thrombocytosis in homozygotes.59 We observed
a similar allele-dose-dependent effect on platelet count in
African Americans. The MPL c.117G>T (p. Lys39Asn)
platelet-count association was not detected previously
through European or African American GWASs9,10 because
the variant is low frequency, specific to African popula-
tions, and not well tagged on the Affy6.0 platform (‘‘tag-
r2’’ ¼ 0.076). In a recent small study of 245 black South
Africans, the MPL c.117G>T (p.Lys39Asn) variant was
nominally associated with platelet count (p ¼ 1.6 3 105),
thus confirming the association in an independent
African-ancestry sample.68
MPL is the platelet and megakaryocyte receptor for
thrombopoietin, or TPO (MIM 600044), an essential regu-
lator of megakaryocyte differentiation and platelet produc-
tion. Primary thrombocytosis, defined as a platelet count
>400 3 109/liter, can be due to rare MPL activating muta-
tions, such as those encoding p.Pro106Leu69 or p.Ser505-
Asn70 amino acid substitutions. Furthermore, acquired
MPL activating mutations, such as those encoding
p.Trp515Leu and p.Trp515Lys substitutions, are found in
a subset of individuals with myeloproliferative disordersJournal of Human Genetics 91, 794–808, November 2, 2012 803
involving high platelet count.71,72 In the case of MPL
c.117G>T (p.Lys39Asn), the mechanism relating reduced
MPL receptor expression to higher platelet count might
seem paradoxical. Reduced amounts of platelet MPLmight
shift the normal negative-feedback loop between circu-
lating platelet count and thrombopoietin levels to higher
TPO and increased platelet production.73,74 In the current
study, we identified a rare MPL variant associated with
higher platelet count, c.754T>C (p.Tyr252His); this
variant lies immediately adjacent to the minimum MPL
binding domain of thrombopoietin (amino acids 206–
251).75 Together with recent GWAS findings for THPO in
Europeans9 and Japanese,4 our results highlight the contri-
bution of common and rare variants of megakaryopoiesis
genes to inter-individual differences in platelet count in
the general population.
We identified genetic variants of platelet surface glyco-
protein receptors suggestively associated with platelet
count. Such variants included those of CD109, CD36,
and ITGB3. ITGB3 rs61736876 (c.557C>T [p.Pro186Leu];
RefSeq NM_000212.2), which encodes a rare p.Pro186Leu
substitution of platelet glycoprotein IIIa, was associated
with lower platelet count. Glycoprotein IIIa p.Pro186Leu
was previously identified in a person with Glanzmann
thrombasthenia (MIM 273800), a congenital platelet
disorder.76 This amino acid substitution interferes with
glycoprotein IIb and IIIa transport to the cell surface,
binding to soluble fibrinogen, and a-v/b-3-mediated cell
spreading on immobilized fibrinogen.76 CD36, or platelet
glycoprotein IV, is a multi-ligand scavenger receptor
found on many cell types. CD36 deficiency (MIM 608404;
Naka-negative blood group) on platelets and monocytes
as a result of null CD36 mutations is common in African
and Asian populations, where CD36 probably also serves
as an erythrocyte malarial receptor.77 Two of these CD36
null mutations, rs3211938 (c.975T>G [p.Tyr325*]) and
rs3211862 (c.158_159insG [p.Asn53Lysfs*4]), along
with the higher-frequency intronic variant rs4731643,
were each associated with lower platelet count in our
African American population. Consistent with these
results, rs3211938 has been associated with decreased
CD36 expression on platelets and monocytes in African
Americans.78,79
Large sample sizes will be required for robustly associ-
ating most rare coding variants with complex traits. Power
calculations are shown for each variant in Tables S2, S4, S5,
and S8. Even with an effective sample size of ~13,000,
power to detect an association with platelet count is only
~10% for the functional variants ITGB3 rs61736876
(c.557C>T [p.Pro186Leu]; MAF 0.007) and CD36
rs3211862 (c.158_159insG [p.Asn53Lysfs*4]; MAF 0.02),
and the effect size is in the range of ~15,000 platelets/ul
(equivalent to approximately 0.25 SD unit). Therefore,
even larger African American samples may be required
for confirmation of associations that did not meet
the threshold of genome-wide significance in the current
study.804 The American Journal of Human Genetics 91, 794–808, NovembAs the cost of whole-genome sequencing continues to
decline, it might soon become feasible to directly genotype
rare variants across the genome in tens of thousands of
samples. However, because the vast majority of the vari-
ants captured through sequencing are exceedingly rare
and outside the protein-coding region, it is not clear how
such data would be analyzed for associations with complex
traits. For variants of intermediate frequency (e.g.,
0.1% < MAF < 5%), we have shown that high-coverage
sequencing for variant discovery followed by imputation
into large GWAS cohorts is a successful and cost-effective
approach for testing associations with complex traits. An
alternative approach involves a combination of low-
coverage exome sequencing in all samples and imputation
with 1000 Genomes Project reference panels.80,81 Similar
to our approach, low-coverage exome sequencing com-
bined with 1000 Genomes imputation has the capability
to capture common and intermediate frequency variation
(1%–5% MAF) with increased power and cost efficiency
in comparison to conventional GWAS.80 Nonetheless,
researchers have not yet used the low-coverage sequencing
approach to discover associations with complex traits, and
our high-coverage sequencing approach might capture
additional imputable lower-frequency coding variants (in
the range of 0.1% to 1% MAF) that would not be discov-
ered through low-coverage exome sequencing. Moreover,
because many rare variants are population specific,
imputation reference panels derived from the same target
population might be important for detecting lower-
frequency alleles and might be less vulnerable to popula-
tion stratification.
By sequencing the entire exomes or protein-coding
regions of the genome in well-phenotyped population-
based samples, the NHLBI GO Exome Sequencing Project
has provided a large exome data set for identifying rare
coding variation underlying a variety of complex traits
related to heart, lung, and blood diseases. The ability to
impute low-frequency coding variants with reasonable
accuracy into larger data sets enables the inclusion of
a greater number of causal coding-sequence variants that
would otherwise not be captured by standard GWASs.
Exome imputation should permit increased power to
detect associations with low-frequency variants, greater
characterization of allelic heterogeneity at previously
known susceptibility loci, and fine mapping of causal
variants.82
Perhaps not surprisingly, all of the newly identified
coding variants explain <0.5% of the variance for any
given trait. For example, the LCT missense variant(s)
explain only 0.2% of WBC variance. Therefore, these rare
coding variants do not appear to contribute substantively
to overall heritability, which has been estimated in the
range of 50% for most blood cell traits.6,83 In prior pub-
lished GWASs of blood cell traits in individuals of Euro-
pean descent, the proportion of variance explained by
common SNPs has been ~1% for hemoglobin and hemat-
ocrit,2 5% for platelet count,9 and ~7% for WBC,5 whereaser 2, 2012
the DARC null variant explains ~15%–20% of the WBC
variance in African Americans.1,6 Therefore, by compar-
ison, the newly identified low-frequency coding variants
explain a very small proportion of variance for each of
the traits examined. Nonetheless, the evidence we found
for allelic heterogeneity at several GWAS loci would not
have been apparent without extending these analyses to
include rare coding variants. Further studies involving
larger samples will be required if we are to assess in
a more comprehensive manner the hypothesis set forth
by Dickson et al.,11 who suggested that multiple rare
variants account for some of the signals for common,
complex traits reported in GWASs.
In summary, imputation of lower-frequency coding
variants identified by whole-exome sequencing into large,
population-based cohorts via population-specific reference
panels offers the opportunity to identify variants that are
associated with complex traits such as blood cell counts
but that have not been previously targeted by genome-
wide genotyping arrays. Studying the genetics of these
quantitative blood traits in diverse populations might
reveal new biologic pathways that ultimately not only
contribute to our understanding of hematopoiesis but
also increase our understanding of the association of blood
counts with cardiovascular, inflammatory, and other
systemic diseases.Supplemental Data
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